BioWorld Science

Feb. 5, 2013

View Archived Issues

Novel candidate JNK1 inhibitors patented

Read More

U.S. group prepares new HCV treatments

Read More

Novo Nordisk releases financial statement for 2012

Read More

Dainippon Sumitomo Pharma updates activities of third quarter of fiscal 2012

Read More

Huntington's disease model extensively characterized

Read More

Study results inform phase III trial design for enterovirus 71 vaccine

Read More

Novel inhibitors of Janus kinases developed at Roche

Read More

Enkephalin analgesics divulged by Pfizer

Read More

Phenex Pharmaceuticals reported new FXR modulators

Read More

Gilead Sciences reports topline results from phase III sofosbuvir studies

Read More

Kymab launches program to develop monoclonal antibody therapeutics

Read More

StemEx product shows efficacy in phase II/III hematological malignancy study

Read More

First patient receives treatment in phase IIa NurOwn stem cell therapy trial

Read More

Pooled data study finds cardiovascular safety similar between peginesatide and comparators

Read More

Japanese government provides funding for unoprostone isopropyl development

Read More

Glenmark Pharmaceuticals discovers novel monoclonal antibody targeting OX40

Read More

The Medicines Company and Alnylam to develop therapeutics for hypercholesterolemia

Read More

Rockwell Medical's PRIME study meets primary endpoint

Read More

Biotest launches Bivigam for primary humoral immunodeficiency

Read More

NAD kinase inhibition has oncolytic potential

Read More

European approval for Zaltrap in metastatic colorectal cancer

Read More

FDA issues complete response letter for Ampligen in chronic fatigue syndrome

Read More

Medigene expands clinical development plan for RhuDex

Read More

Preclinical findings show promise of hpSC-derived neuronal cells for Parkinson's disease

Read More

Idenix discontinues IDX-184 and IDX-19368 HCV programs

Read More